Today: 21 May 2026
Browse Category

NYSE:BRK.B 17 August 2025 - 30 September 2025

Warren Buffett’s $10B Oil Bet: Could Berkshire’s OxyChem Deal Supercharge Occidental (OXY)?

Warren Buffett’s $10B Oil Bet: Could Berkshire’s OxyChem Deal Supercharge Occidental (OXY)?

Warren Buffett’s Berkshire Hathaway is in talks to buy Occidental Petroleum’s OxyChem unit for about $10 billion, according to Reuters and Bloomberg. Occidental’s long-term debt stood at $23.3 billion as of June 2025 after major acquisitions. The company has sold assets and repaid $7.5 billion in debt since July 2024. OXY shares are down 2.4% year-to-date, lagging peers.
30 September 2025
····
CSX CEO Abruptly Departs Amid Rail Merger Frenzy – What’s Next?

CSX CEO Abruptly Departs Amid Rail Merger Frenzy – What’s Next?

CSX named Steve Angel as its new President and CEO, effective Sept. 28, replacing Joe Hinrichs after investor pressure for leadership change and potential rail consolidation. The move follows hedge fund Ancora Holdings’ public criticism of CSX’s performance and calls for a merger. Angel previously led Praxair and Linde. The announcement comes as industry rivals Union Pacific and Norfolk Southern pursue an $85 billion merger.
29 September 2025
······
Global Business Weekend: Record Highs, AI Shake-ups, Oil Bears & Major Deals

Global Business Weekend: Record Highs, AI Shake-ups, Oil Bears & Major Deals

The Dow Jones Industrial Average hit a record intraday high, surpassing its December peak, as UnitedHealth shares jumped 9.5% after Berkshire Hathaway disclosed a stake. Nvidia’s market value reached $4 trillion. Apple announced an additional $100 billion investment in U.S. projects. Meta Platforms reorganized its AI teams and secured $29 billion in financing for data centers.
17 August 2025
·········
1 2 3 4

Stock Market Today

  • Amplitech Group, Inc. (AMPG) Stock Price and Performance Analysis
    May 21, 2026, 2:56 AM EDT. Amplitech Group, Inc. (AMPG) stock returns are presented as cumulative figures over 1 to 4 years ending March 4, 2021, with historical data provided from 2017 to 2021. Past performance is not indicative of future results. The analysis is delivered by Gotrade Securities Inc., a Labuan-licensed entity governed by the Labuan Financial Services and Securities Act 2010. Investors are cautioned that investments carry risks including potential capital loss. This report serves informational purposes only and does not constitute a solicitation or offer to buy or sell securities, nor is it a brokerage account invitation. Distribution restrictions apply outside certain jurisdictions, including the United States.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop